Narayanam Srikanth

Narayanam Srikanth

orcid
Deputy Director General, Central Council for Research in Ayu...

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Journal of Ayurveda and Integrative Medicine
Verified
Journal Article
Open access
MGManohar S. Gundeti
Manohar S. Gundeti
LBLaxman W. Bhurke
Laxman W. Bhurke
PMPallavi S. Mundada
Pallavi S. Mundada
SMSanjay Murudkar
Sanjay Murudkar
ASAshita Surve
Ashita Surve
KDK.S. Dhiman
K.S. Dhiman
Influenza-like Illness (ILI) refers to a wide range of viral infections with an important cause of morbidity and mortality worldwide. The global incidence of ILI is estimated at 5-10% in adults and 20-30% in children. In India influenza accounts for 20-42% of monthly acute medical illness hospitalizations during the peak rainy season. AYUSH-64, a poly-herbal drug, is in practice for 40 years for various clinical conditions like fevers, microfilaremia, and inflammatory conditions. A pilot study was conducted to evaluate the safety and efficacy of Ayurvedic formulation, AYUSH-64 in clinically diagnosed ILI for accelerating the recovery. A prospective, open-label, nonrandomized, single group, single-center pilot clinical study with pre-test and post-test design was conducted at Raja Ramdeo Anandilal Podar Central Ayurveda Research Institute for Cancer, Mumbai, an institute of Central Council for Research in Ayurvedic Sciences (CCRAS) between June 2018 and July 2019. A total of 38 participants of clinically diagnosed ILI (18-65 years) were studied with an one-week intervention of 'AYUSH 64' in a dose of 3 gm/day and three weeks post-treatment observation period. Assessment of parameters viz. improvement in the symptoms of ILI, frequency of usage of acetaminophen, antihistaminic and cough syrup, hematology, liver function and kidney function tests along with incidence of secondary complications, and time to return to a normal routine was done. One-week intervention of AYUSH 64 helped to recover from ILI symptoms with reduced frequency of usage of acetaminophen and antihistaminic. The intervention was safe on hematology and biochemical parameters. No serious adverse effects were observed during the study. AYUSH 64 along-with standard care in ILI is safe and efficacious and this may be used in other viral infections with pyrexia as add-on to standard care for early recovery and better outcome.

1 January 2022 in Journal of Ayurveda and Integrative Medicine
Verified
Journal Article
Open access
STSaketh Ram Thrigulla
Saketh Ram Thrigulla
MMManne Munikumar
Manne Munikumar
VRVankudavath Naik Raju
Vankudavath Naik Raju
PDParasannanavar Devaraj
Parasannanavar Devaraj
NBNaveen Kumar Boiroju
Naveen Kumar Boiroju
KDK.S. Dhiman
K.S. Dhiman
Outbreak of Corona Virus Disease in late 2019 (COVID-19) has become a pandemic global Public health emergency. Since there is no approved anti-viral drug or vaccine declared for the disease and investigating existing drugs against the COVID-19. AYUSH-64 is an Ayurvedic formulation, developed and patented by Central Council of Research in Ayurvedic Sciences, India, has been in clinical use as anti-malarial, anti-inflammatory, anti-pyretic drug for few decades. Thus, the present study was undertaken to evaluate AYUSH-64 compounds available in this drug against Severe Acute Respiratory Syndrome-Corona Virus (SARS-CoV-2) Main Protease (Mpro; PDB ID: 6LU7) via in silico techniques. Different molecular docking software’s of Discovery studio and Auto Dock Vina were used for drugs from selected AYUSH-64 compounds against SARS-CoV-2. We also conducted 100 ns period of molecular dynamics simulations with Desmond and further MM/GBSA for the best complex of AYUSH-64 with Mpro of SARS-CoV-2. Among 36 compounds of four ingredients of AYUSH-64 screened, 35 observed to exhibits good binding energies than the published positive co-crystal compound of N3 pepetide. The best affinity and interactions of Akuammicine N-Oxide (from Alstonia scholaris) towards the Mpro with binding energy (AutoDock Vina) of -8.4 kcal/mol and Discovery studio of Libdock score of 147.92 kcal/mol. Further, molecular dynamics simulations with MM-GBSA were also performed for Mpro– Akuammicine N-Oxide docked complex to identify the stability, specific interaction between the enzyme and the ligand. Akuammicine N-Oxide is strongly formed h-bonds with crucial Mpro residues, Cys145, and His164. The results provide lead that, the presence of Mpro– Akuammicine N-Oxide with highest Mpro binding energy along with other 34 chemical compounds having similar activity as part of AYUSH-64 make it a suitable candidate for repurposing to management of COVID-19 by further validating through experimental, clinical studies.

1 April 2011 in Fitoterapia
Verified
Journal Article
Closed access
SPSubrata Pandit
Subrata Pandit
MKMukherjee Pulok K
Mukherjee Pulok K
PSPonnusankar Sivasankaran
Ponnusankar Sivasankaran
MVMurugan Venkatesh
Murugan Venkatesh
Narayanam SrikanthNarayanam Srikanth
Narayanam Srikanth

20 September 2023 in Chemistry & Biodiversity
Verified
Journal Article
Closed access
YGYashika Gandhi
Yashika Gandhi
SPShyam Baboo Prasad
Shyam Baboo Prasad
VKVijay Kumar
Vijay Kumar
HSHemant Soni
Hemant Soni
HRHemant Rawat
Hemant Rawat
TWThomas J. Webster
Thomas J. Webster

1 January 2012 in AYU (An International Quarterly Journal of Research in Ayurveda)
Verified
Journal Article
Open access
PDF file
YDYadu Nandan Dey
Yadu Nandan Dey
Narayanam SrikanthNarayanam Srikanth
Narayanam Srikanth
MWManish Wanjari
Manish Wanjari
SOSarada Ota
Sarada Ota
MJMahvish Jamal
Mahvish Jamal
Amorphophallus paeoniifolius is used for long period in various chronic diseases therapeutically. Aim of the current review is to search literature for the pharmacological properties, safety/toxicity studies, pharmacognostic studies and phytochemical investigation of Amorphophallus paeoniifolius tuber. The compiled data may be helpful for the researchers to focus on the priority areas of research yet to be discovered. Complete information about the plant has been collected from various books, journals and Ayurvedic classical texts like Samhitas, Nighantus etc. Journals of the last 20 years were searched. Particulars of pharmacological activities, phytochemical isolation, toxicity studies etc. were extracted from the published reports focussing on the safety profile of the plant. Safety of the whole plant was concluded in the review.

7 May 2021 in JMIRx Med
Verified
Journal Article
Open access
Narayanam SrikanthNarayanam Srikanth
Narayanam Srikanth
RRRakesh Rana
Rakesh Rana
RSRicha Singhal
Richa Singhal
SJSophia Jameela
Sophia Jameela
RSRajeshwari Singh
Rajeshwari Singh
KDK S Dhiman
K S Dhiman
Background: India follows a pluralistic system for strategic and focused health care delivery in which traditional systems of medicine such as Ayurveda, yoga and naturopathy, Unani, Siddha, Sowa Rigpa, and homoeopathy (AYUSH) coexist with contemporary medicine, and this system functions under the Ministry of AYUSH (MoA). The MoA developed a mobile app, called AYUSH Sanjivani, to document the trends of the use of AYUSH-based traditional and holistic measures by the public across India. Analysis of the data generated through this app can help monitor the extent of the use of AYUSH measures for maintenance of health during the COVID-19 pandemic and aid effective health promotion and communication efforts focused on targeted health care delivery during the pandemic. Objective: The purpose of the study was to determine the extent of use of AYUSH measures by the public in India for maintenance of health during the COVID-19 pandemic as reported through the AYUSH Sanjivani mobile app. Methods: Cross-sectional analysis of the data generated through the Ayush Sanjivani app from May 4 to July 31, 2020, was performed to study the pattern and extent of the use of AYUSH-based measures by the Indian population. The responses of the respondents in terms of demographic profile, use pattern, and benefits obtained; the association between the use of AYUSH-based measures and symptomatic status; and the association between the duration of use of AYUSH-based measures and the outcome of COVID-19 testing were evaluated based on bivariate and multivariate logistic regression analysis. Results: Data from 723,459 respondents were used for the analysis, among whom 616,295 (85.2%) reported that they had been using AYUSH measures for maintenance of health during the COVID-19 pandemic. Among these 616,295 users, 553,801 (89.8%) either strongly or moderately agreed to have benefitted from AYUSH measures. Ayurveda and homeopathic measures and interventions were the most preferred by the respondents across India. Among the 359,785 AYUSH users who described their overall improvement in general health, 144,927 (40.3%) rated it as good, 30,848 (8.6%) as moderate, and 133,046 (40.3%) as slight. Respondents who had been using AYUSH measures for less than 30 days were more likely to be COVID-19–positive among those who were tested (odds ratio 1.52, 95% CI 1.44-1.60). The odds of nonusers of AYUSH measures being symptomatic if they tested positive were greater than those of AYUSH users (odds ratio 4.01, 95% CI 3.61-4.59). Conclusions: The findings of this cross-sectional analysis assert that a large proportion of the representative population practiced AYUSH measures across different geographic locations of the country during the COVID-19 pandemic and benefitted considerably in terms of general well-being, with a possible impact on their quality of life and specific domains of health.